Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 10/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | RAB9A | P51151 | 2/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.77 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.74 |
| ▸ | KCNK9 | Q9NPC2 | 9/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.63 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15603529 | 0.94 | KCNK3 (0.82) | KCNK3MEN1KMT2ARAB9AHTT | |
| SCHEMBL12764066 | 0.90 | KCNK3 (0.70) | KCNK3MEN1KMT2ARAB9AHTT | |
| SCHEMBL7293743 | 0.88 | KCNK3 (0.86) | KCNK3MEN1KMT2ARAB9AHTT | |
| SCHEMBL12764063 | 0.87 | MEN1 (1.00) | KCNK3MEN1KMT2ARAB9AHTT | |
| SCHEMBL12201888 | 0.86 | HDAC8 (0.74) | KCNK3MEN1KMT2ARAB9AHTT | |
| SCHEMBL4253897 | 0.86 | KCNK3 (0.93) | KCNK3MEN1KMT2ARAB9AHTT | |
| SCHEMBL21378088 | 0.84 | KCNK3 (0.72) | KCNK3MEN1KMT2ARAB9AHTT | |
| SCHEMBL15603515 | 0.84 | MAPT (0.81) | KCNK3MEN1KMT2ARAB9AHTT | |
| SCHEMBL20073524 | 0.84 | MAPT (0.81) | KCNK3MEN1KMT2ARAB9AHTT | |
| SCHEMBL15603524 | 0.84 | HDAC8 (0.78) | KCNK3MEN1KMT2ARAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105528-A1 | PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS | BRANDEIS UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105528-A1 | PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K5 | KCNK3 1670/4885MEN1 2205/4885KMT2A 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.